The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Familial Mediterranean Fever-Associated AA Amyloidosis

Reactive systemic amyloid A (AA) amyloidosis arising as a long-term complication of inadequately controlled familial Mediterranean fever, most commonly affecting the kidneys and progressing to nephrotic syndrome and end-stage kidney disease.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Familial Mediterranean Fever-Associated AA Amyloidosis?

AA amyloidosis associated with familial Mediterranean fever (FMF) results from chronic overproduction of serum amyloid A protein during persistent or subclinical inflammation in MEFV-mutated patients, leading to extracellular deposition of misfolded AA fibrils, predominantly in the kidneys.

Renal involvement is typically the dominant manifestation: it begins with persistent proteinuria, progresses to nephrotic-range proteinuria, and culminates in chronic kidney disease and ultimately end-stage kidney disease over years; the gastrointestinal tract, spleen, and adrenal glands may also be affected.

Risk factors include the homozygous M694V MEFV genotype, country of origin, male sex, late-onset disease, persistent SAA elevation despite colchicine, and poor adherence; treatment requires intensified colchicine and IL-1 blockade with anakinra or canakinumab to suppress SAA, with renal replacement therapy and possible kidney transplantation in advanced disease.

Symptoms

Persistent or worsening proteinuria detected on routine urinalysis in an FMF patient
Peripheral edema, weight gain, and frothy urine indicating nephrotic syndrome
Progressive fatigue, anemia, and biochemical features of chronic kidney disease
Episodes of FMF (recurrent fever, peritonitis, pleuritis, arthritis) that have become more frequent or severe
Hepatosplenomegaly and unexplained gastrointestinal symptoms (chronic diarrhea, malabsorption) in advanced disease
Persistently elevated acute-phase reactants (CRP, SAA) between FMF attacks

Risk Factors

Homozygous or compound heterozygous M694V MEFV mutations
Origin from high-risk populations: Sephardic Jews, Armenians, Turks, Arabs
Late diagnosis or non-adherence to colchicine therapy
Persistent elevation of serum amyloid A despite seemingly adequate FMF control
Male sex and family history of FMF-associated amyloidosis
Coexistence of other chronic inflammatory disorders such as inflammatory bowel disease or chronic infections

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Any new-onset proteinuria or persistent dipstick proteinuria in a patient with FMF — urgent nephrology referral
  • Edema, weight gain, or hypoalbuminemia suggestive of nephrotic syndrome
  • Worsening or breakthrough FMF attacks despite colchicine — rheumatology evaluation for IL-1 blockade
  • Persistently elevated CRP or SAA between attacks during routine FMF follow-up
  • Family history of FMF-associated AA amyloidosis combined with high-risk genotype

Treatment Methods

01
Maximal tolerated colchicine therapy with monitoring of trough levels and meticulous attention to adherence and drug interactions
02
IL-1 blockade with anakinra (daily subcutaneous) or canakinumab (every 4 to 8 weeks) for colchicine-resistant or amyloid-progressive disease
03
Targeted control of SAA below 10 mg/L by serial monitoring; lipid, blood pressure, and renin-angiotensin-aldosterone blockade for renoprotection
04
Renal replacement therapy with hemodialysis or peritoneal dialysis in end-stage kidney disease, plus kidney transplantation in selected patients with stable inflammatory control
05
Multidisciplinary follow-up by rheumatology, nephrology, and genetics, along with patient education on lifelong adherence

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.